SCHEMBL11948699

SCHEMBL11948699

COc1ccc2c(CC(=O)N(C)OC)coc2c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.58
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
HPGD P15428 1/20 0.57
ALOX12 P18054 1/20 0.57
ALDH1A1 P00352 5/20 0.56
GAA P10253 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
RAB9A P51151 4/20 0.55
TSHR P16473 2/20 0.54
L3MBTL1 Q9Y468 3/20 0.53
PKM P14618 1/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
USP2 O75604 2/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25029852 0.90 MAPT (0.60) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL204937 0.82 MAPT (0.67) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL11948695 0.81 MAOB (0.45) MAPTKDM4EMEN1KMT2AHPGD
SCHEMBL2431256 0.81 ALDH1A1 (0.67) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL1104011 0.81 MAPT (0.62) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL1104010 0.81 MAPT (0.62) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL23117308 0.81 L3MBTL1 (0.67) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL21807610 0.79 MAPT (0.60) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL23188008 0.77 CYP11B1 (0.57) MAPTTDP1KDM4EMEN1KMT2A
SCHEMBL8237113 0.75 ALDH1A1 (0.46) KDM4EHPGDALDH1A1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232298-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA N.V. (BE) 2012-07-31 US disclosed
US-20090149493-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN-CILAG (FR) 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149493-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 TP53, MDM2, TP53BP1 MAPT 802/4885TDP1 329/4885KDM4E 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.